This multicenter intention-to-treat double blinded randomized controlled trial will evaluate the utility of PGT-A to achieve sustained implantation after a single embryo transfer in women of advanced maternal age (35-40). Secondary objectives include the development of time-lapse non-invasive and cell division origin of aneuploidy analysis methods to better predict mosaicism. Eligible participants will receive free LifeView PGT-A.

Patient perspectives on the prospect of reducing polygenic disease risk will be instrumental in future applications of LifeView PGT-P. This study will evaluate decisions made by patients using PGT-A, including the impact of known family history and the number of euploid embryos available for ranking with the Embryo Health Score. Eligible participants will receive free LifeView PGT-P.

Genomic Prediction has developed a would-be parent test to identify carriers of the Annexin A5 M2 Haplotype. Carriers have an increased risk of several pregnancy complications. However, when informed with test results, carriers can opt for either low molecular weight heparin treatment or PGT-M for M2 to improve the chance of achieving term delivery. This observational study will investigate history of pregnancy complications, decision making, and IVF outcomes in carrier patients. Eligible participants will receive free LifeView M2 testing.